We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.94%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.45B
AUM Growth
+$719M
Cap. Flow
+$643M
Cap. Flow %
6.8%
Top 10 Hldgs %
29.09%
Holding
237
New
15
Increased
96
Reduced
78
Closed
21

Top Buys

Rank Stock Value
1
ACCD
Accolade Inc
ACCD
+$56.6M
2
RVMD icon
Revolution Medicines
RVMD
+$46M
3
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$43.7M
4
EPIX
ESSA Pharma
EPIX
+$42.4M
5
BDX icon
Becton Dickinson
BDX
+$33.4M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$86.9M
2
HALO icon
Halozyme
HALO
+$47.2M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$38.1M
4
ESPR
Esperion Therapeutics
ESPR
+$33.9M
5
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$33.3M

Sector Composition

Rank Sector Weight
1 Healthcare 95.93%
2 Industrials 0.88%
3 Technology 0.47%
4 Consumer Discretionary 0.04%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$404M 4.27%
8,984,234
-65,858
-0.7% -$3.67M
MRNA icon
2
Moderna
MRNA
$24.5B
$368M 3.89%
2,809,950
-136,963
-5% -$19.8M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$318M 3.37%
3,274,551
-122,100
-4% -$12.8M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$296M 3.13%
1,376,704
+137,719
+11% +$30.2M
ARGX icon
5
argenx
ARGX
$53.8B
$263M 2.78%
954,554
+9,206
+1% +$2.91M
INCY icon
6
Incyte
INCY
$23.4B
$244M 2.58%
3,005,700
-3,000
-0.1% -$256K
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.36B
$234M 2.48%
4,537,092
+336,090
+8% +$16.6M
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$35.7B
$230M 2.43%
1,627,114
+23,614
+1% +$3.55M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$200M 2.12%
1,308,728
-84,300
-6% -$13M
MGNX icon
10
MacroGenics
MGNX
$285M
$192M 2.03%
6,027,926
+123,409
+2% +$3M
FATE icon
11
Fate Therapeutics
FATE
$324M
$182M 1.93%
2,209,336
+101,836
+5% +$9.76M
ABT icon
12
Abbott
ABT
$175B
$167M 1.77%
1,392,999
-3,874
-0.3% -$459K
ISRG icon
13
Intuitive Surgical
ISRG
$122B
$163M 1.73%
662,325
+74,265
+13% +$18.7M
RDUS
14
DELISTED
Radius Health, Inc.
RDUS
$157M 1.66%
7,531,414
– –
BIIB icon
15
Biogen
BIIB
$30.4B
$156M 1.65%
558,400
-5,600
-1% -$1.51M
ELV icon
16
Elevance Health
ELV
$80.9B
$138M 1.46%
385,548
+49,755
+15% +$16M
ARVN icon
17
Arvinas
ARVN
$517M
$137M 1.45%
2,071,503
-120,000
-5% -$9.18M
SAGE
18
DELISTED
Sage Therapeutics
SAGE
$136M 1.43%
1,810,704
+243,200
+16% +$19.9M
UNH icon
19
UnitedHealth
UNH
$387B
$133M 1.41%
357,381
+51,336
+17% +$17.8M
BMY icon
20
Bristol-Myers Squibb
BMY
$124B
$132M 1.39%
2,085,152
+280,680
+16% +$17.5M
HALO icon
21
Halozyme
HALO
$9.23B
$126M 1.33%
3,011,966
-1,033,034
-26% -$47.2M
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$124M 1.31%
3,659,919
– –
HUM icon
23
Humana
HUM
$48B
$121M 1.28%
288,719
+51,652
+22% +$20.6M
CRSP icon
24
CRISPR Therapeutics
CRSP
$4.71B
$119M 1.26%
978,384
+68,700
+8% +$10.4M
PODD icon
25
Insulet
PODD
$11.4B
$113M 1.2%
434,188
+96,720
+29% +$25.9M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2021 Portfolio in Review

As of Q1 2021, Bellevue Group held 237 positions worth $9.45B, up 8.2% from $8.73B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $643M of net new capital in Q1 2021, opening 15 new positions and adding to 96 existing holdings. Its largest new stake was ESSA Pharma: 1,825,814 shares worth $53M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $86.9M trimmed.

  • Bellevue Group's largest Q1 2021 buy was ESSA Pharma: 1,825,814 shares worth $53M.
  • Bellevue Group added most to Accolade Inc in Q1 2021, an estimated $56.6M increase.
  • Bellevue Group's biggest Q1 2021 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $86.9M.
  • Bellevue Group fully exited GenMark Diagnostics, Inc in Q1 2021, selling an estimated $38.1M.
  • Bellevue Group's ten largest holdings make up 29% of its $9.45B portfolio in Q1 2021.
  • Bellevue Group opened 15 new positions and closed 21 in Q1 2021.
  • Bellevue Group's portfolio value rose 8.2% quarter-over-quarter to $9.45B.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.